Nasus Pharma Ltd Income (Loss) from Continuing Operations, Per Diluted Share
Nasus Pharma Ltd (NSRX) reported Income (Loss) from Continuing Operations, Per Diluted Share of -$0.72 per share for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2026-03-25
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month |
|---|---|---|
| 2025-12-31 | -$0.72 20-F · filed 2026-03-25 | |
| 2025-06-30 | -$0.16 6-K · filed 2025-12-29 | |
| 2024-12-31 | -$0.22 20-F · filed 2026-03-25 | |
| 2024-06-30 | -$0.13 6-K · filed 2025-12-29 | |
| 2023-12-31 | -$0.19 20-F · filed 2026-03-25 |